Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Apex Capital’s Top Tech Picks For Q2

Page 1 of 2

Apex Capital is a San Francisco-based long/short equity fund founded by Sanford J. Colen in 1995. The fund recently filed its 13F with the Securities and Exchange Commission (SEC) for the reporting period of June 30. According to the filing, the fund’s public equity portfolio at the end of the second quarter constituted 48 positions worth over $1.15 billion. Consumer discretionary, healthcare, and information technology were the fund’s top sectoral picks for the quarter, with stocks from these accounting for 30%, 27%, and 21% of the fund’s equity portfolio respectively. The filing revealed that during the April-June period Apex Capital initiated a position in ten stocks, increased its position in 17 stocks, reduced its stake in 21 stocks, and liquidated its entire holdings in 14 previously-held stocks. In this article we are going to analyze Apex Capital’s three biggest tech bets heading into the third quarter: Netflix, Inc. (NASDAQ:NFLX)MicroStrategy Incorporated (NASDAQ:MSTR), and Cornerstone OnDemand, Inc. (NASDAQ:CSOD).

Netflix, Inc. (NASDAQ:NFLX), Picture, Sign, Logo, Brand, Snowman, Special edition red envelopes,

s_bukley /

At Insider Monkey, we track hedge funds’ moves in order to identify actionable patterns and profit from them. Our research has shown that hedge funds’ large-cap stock picks historically underperformed the S&P 500 Total Return Index by an average of seven basis points per month between 1999 and 2012. On the other hand, the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Index by an average of 95 basis points per month (read the details here). Since the official launch of our small-cap strategy in August 2012, it has performed just as predicted, returning over 123.1% and beating the market by more than 65.5 percentage points. We believe the data is clear: investors will be better off by focusing on small-cap stocks utilizing hedge fund expertise (while avoiding their high fees at the same time) rather than large-cap stocks.

Sanford J. Colen
Sanford J. Colen
Apex Capital

Netflix, Inc. (NASDAQ:NFLX) continued to remain Apex Capital’s top pick, even though the fund sold 441,700 shares of the company during the second quarter. This large share sale can mostly be attributed as profit booking, as shares of Netflix, Inc. (NASDAQ:NFLX) have had an unprecedented rise in 2015, up by 57.7% during the second quarter alone. As of June 30, Apex owned over 1.19 million shares of Netflix, Inc. (NASDAQ:NFLX) worth $111.9 million. It’s interesting to note that the fund’s stake in Netflix, Inc. (NASDAQ:NFLX) at the end of June was still worth more than its stake in the company at the end of March. The company again managed to surprise Wall Street by reporting much better than expected numbers for the second quarter on July 15. Revenue for the quarter was up by 22.7% year-over-year to $1.65 billion, while adjusted EPS of $0.06 came in above analysts’ expectation of $0.04. During the second quarter, Netflix, Inc. (NASDAQ:NFLX) added 3.3 million subscribers, bringing its total subscriber count to an all-time high of 65 million. Karthik Sarma‘s SRS Investment Management increased its position in the company by 400% during the first quarter. However, legendary activist investor Carl Icahn recently tweeted that he had sold his entire stake in Netflix, Inc. (NASDAQ:NFLX).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!